Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics
- Sandoz gains rights to three established brands sold in more than 100 markets
- Transaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading position in cephalosporins
- Acquisition confirms Sandoz commitment to antibiotics, following announcement of further investment plans for European-based manufacturing network
Basel, October 11, 2021 – Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotics business.
Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum)) in more than 100 markets, further reinforcing its leading global position in antibiotics. In 2020, the three brands had combined sales of approximately USD 140 million in the relevant markets.
“Antibiotics are the backbone of modern healthcare systems and a central pillar of our worldwide Sandoz patient offering”, said Sandoz CEO Richard Saynor. “The successful and timely closing of this important transaction is further proof of our commitment at Sandoz to be a leading global supplier of these essential medicines.
“Cephalosporins are the largest antibiotic segment by global sales and this acquisition complements our #1 position in generic penicillins, the other key segment. It also sets us up for additional synergies driven by an increased promotional footprint across markets.”
The transaction excludes rights to certain brands previously divested by GSK in the US, Australia and Germany. GSK will also retain full brand rights in China (excluding Taiwan, Hong Kong and Macau), India, Pakistan, and Egypt and to certain brands in Japan.
In line with its integrated manufacturing strategy, Sandoz intends in the longer term to manufacture Zinnat at sites in its own network, which has global antibiotics production centered on its lead production site in Kundl, Austria. In May, Sandoz announced plans to invest more than EUR 150 million in its uniquely vertically-integrated, European-based antibiotics network.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plans,” “commitment,” “to acquire,” “to expand,” “expected,” “intends,” “expect,” “focus,” “complements,” “leading,” or similar terms, or by express or implied discussions regarding the agreement to acquire GSK’s cephalosporin antibiotics business; or regarding potential future revenues from Zinnat, Zinacef or Fortum. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the expected benefits or synergies from the transaction described in this press release will be achived in the expected timeframe, or at all. Neither is there any guarantee that Zinnat, Zinacef or Fortum will be commercially successful in the future. In particular, our expectations regarding the transaction described in this press release and Zinnat, Zinacef and Fortum could be affected by, among other things, regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2020 sales of USD 9.6 billion.
Sandoz on social media:
CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/
Novartis and Sandoz Global Communications
E-mail : firstname.lastname@example.org
| Richard Jarvis|
Novartis Global Communications
+41 79 584 23 26 (mobile)
| Chris Lewis|
Sandoz Global Communications
+49 174 244 9501 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 778 5052|
| Thomas Hungerbuehler |
| +41 61 324 8425|
+41 61 324 7188
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Scientific Beta welcomes updated TCFD guidance and renews criticism of EU Climate Transition and Paris-Aligned Benchmark Regulation21.10.2021 10:21:50 CEST | Press release
Press Release - Boston, London, Nice, Paris, Singapore, Tokyo, October 21, 2021 Scientific Beta welcomes updated TCFD guidance and renews criticism of EU Climate Transition and Paris-Aligned Benchmark Regulation Index provider reiterates warnings against use of enterprise-value based carbon intensity and regards integration of implied temperature rise metrics into portfolio construction as premature On 15 October 2021, the Task Force on Climate-related Financial Disclosures (TCFD) updated its 2017 guidelines on implementing its recommendations that aim to promote more informed financial decisions in relation to the risks of climate change.1 The updated guidance: Promotes more granular or explicit disclosure of risks and opportunities identified by reporting organisations and how these impact their strategiesIntroduces significant revisions to the disclosures of metrics and targets to: Encourage the uptake of indicators that are relevant across industries and of related targetsRequire d
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS21.10.2021 10:10:00 CEST | Press release
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-10-21Loan194Coupon1.00 %ISIN-codeSE0012142206Maturity2024-09-18 Tendered volume, SEK mln500 +/- 250 Volume offered, SEK mln1,950 Volume bought, SEK mln500 Number of bids7 Number of accepted bids3 Average yield0.177 %Lowest accepted yield0.176 %Highest yield0.178 %% accepted at lowest yield 30.00 Auction date2021-10-21Loan1590Coupon1.00 %ISIN-codeSE0012676690Maturity2025-09-03 Tendered volume, SEK mln1,700 +/- 850 Volume offered, SEK mln4,200 Volume bought, SEK mln1,700 Number of bids6 Number of accepted bids2 Average yield0.378 %Lowest accepted yield0.378 %Highest yield0.381 %% accepted at lowest yield 85.29 Auction date2021-10-21Loan145Coupon1.00 %ISIN-codeSE0012481349Maturity2024-06-12 Tendered volume, SEK mln800 +/- 400 Volume offered, SEK mln2,400 Volume bought, SEK mln800 Number of bids5 Number of accepted bids1 Average yield0.115 %Lowest accepted yield0.115 %Highest yield0.115 %% accepted at lowest yield 100.
Kraftigere innsats kreves for kursendring mot klimamål21.10.2021 09:00:00 CEST | Pressemelding
(Oslo, 21. oktober 2021) -- Statkraft’s årlige Lavutslippsscenario maner til langt sterkere handling for å styre verden i retning av å nå 1,5-gradersmålet. Fornybar kraftproduksjon utgjør fortsatt kjernen i en slik strategi, men vi vil ikke lykkes uten utslippsfritt hydrogen, ifølge rapporten. - Verden er mobilisert til å samarbeide med ett mål for øyet – å redusere oppvarmingen av planeten vår. Dette er århundrets viktigste oppdrag, og vil definere vår generasjon. Med gradvis gjenåpning av samfunnet, stiger utslippene tilbake til nivåene fra før pandemien. Dette forsterker vårt syn om at en storstilt omlegging av energisystemet er helt nødvendig for å nærme oss en 1,5-gradersbane, sier konsernsjef Christian Rynning-Tønnessen i Statkraft. Hvert år utvikler Statkraft sitt Lavutslippsscenario, en omfattende analyse av utviklingen i verdens energimarkeder. Analysen danner grunnlaget for Statkrafts framtidige investeringer og for sjette året på rad deler vi nå våre nøkkelfunn: GRØNNE INVES
Greater action needed to shift global course to meet climate target21.10.2021 09:00:00 CEST | Press release
(Oslo, 21 October 2021) -- Statkraft’s annual Low Emissions Scenario urges greater action to shift global course to come close to a 1.5-degree climate target. Renewables remain at the core of this strategy, but we won’t succeed without clean hydrogen, according to the report. “The world has been called to arms, to work in unison to slow the warming of our planet. It’s the mission of a lifetime, one that will define our generation. With the world slowly re-opening, so too are emissions returning to pre-pandemic levels, reinforcing our belief that the only way towards a 1.5-degree path is through the energy transition,” says Statkraft Chief Executive Officer Christian Rynning-Tønnesen. Each year, Europe’s largest renewable energy generator develops its Low Emissions Scenario, analysing developments in the global energy markets. The analysis is used as a foundation for Statkraft’s future investments and for the sixth consecutive year, we now share our key findings: GREEN INVESTMENTS: Grow
Invitation to the press conference on Aspo's Interim report21.10.2021 09:00:00 CEST | Press release
Aspo Plc Press Release October 21, 2021 at 10 a.m. Invitation to the press conference on Aspo'sInterim report Aspo Plc will publish the Interim report for January-September 2021 on Wednesday, October 27, 2021, approximately at 9.30 a.m. Finnish time. A press conference for analysts, investors and media will be held at FLIK studio Eliel in Sanoma House (Töölönlahdenkatu 2, 00100 Helsinki, entrance inside the Sanoma House) on Wednesday, October 27, 2021 at 2 p.m. The Interim report will be presented by CEO Rolf Jansson, and the event will be held in Finnish. The presentation material will be available at www.aspo.com before the press conference. Registration beforehand to email@example.com, by Monday, October 25, 2021, at the latest. The press conference will be held in Finnish and it can also be followed by a live webcast at https://aspo.videosync.fi/2021-q3-results, or by calling +358 9 817 10310 (62598237#) 5 to 10 minutes before the beginning of the press conference. The recor
GeoJunxion (GOJXN.AS) is pleased to publish its 2020-‘21 Annual Accounts for the year ending 30 June 202121.10.2021 08:30:00 CEST | Press release
Capelle aan den IJssel, The Netherlands – 21 October 2021 – GeoJunxion (GOJXN.AS) publishes its 2020-’21 Annual Accounts for the 18-month accounting year ending 30 June 2021. We are delighted to present the GeoJunxion Annual Report for the accounting year 2020-21. It covers the 18-month period from 1 January 2020 to 30 June 2021. However, the comparative financials for 2019 relate to the 12-month period from 1 January to 31 December 2019. A copy of the document is attached to this press release and can be found on the company’s website www.geojunxnion.com, under the investor relations section. The 2020-21 accounting year was an eventful period during which the company underwent a complete metamorphosis. At the same time, we realized significant top line growth whilst keeping operating expenses flat on a like for like basis and significantly reduced the operating losses. All this during a time severely impacted by the COVID-19 pandemic. A summary of the key financials is provided in the
PGS ASA: Third Quarter 2021 Results21.10.2021 08:00:00 CEST | Press release
Further Contract Market Improvement Muted Late Sales Takeaways Q3 2021 Segment Revenues and Other Income of $131.7 million, compared to $116.1 million in Q3 2020Segment EBITDA of $55.6 million, compared to $88.4 million in Q3 2020Segment EBIT loss (excluding impairments and other charges) of $39.5 million, compared to profit of $0.5 million in Q3 2020Segment MultiClient pre-funding revenues of $35.3 million, with a corresponding pre-funding level of 101%, compared to $50.4 million and 89%, respectively, in Q3 2020Cash flow from operations of $114.5 million, compared to $65.9 million in Q3 2020 As Reported Revenues and Other Income according to IFRS of $141.7 million and an EBIT loss of $29.9 million, compared to $85.1 million and an EBIT loss of $4.3 million, respectively, in Q3 2020Awarded 3D acquisition contract by ExxonMobil for work offshore SurinameSecured pre-funding for Sarawak MultiClient campaignFirst significant carbon capture and storage (CCS) specific MultiClient sale “In t